Mar 7, 2019

Scott Gottlieb's legacy of experimental drug approvals

Expand chart
Data: Evaluate; Chart: Axios Visuals

Outgoing Food and Drug Administration Commissioner Scott Gottlieb presided over 2 years of relative leniency toward novel drug therapies, according to an Evaluate analysis.

Why it matters: While this was good for investors and drug companies, the impact on patients isn't yet clear. Most of these experimental approvals were for cancer drugs, which can get approved quickly for end-of-life care when a patient is out of options.

Details: In 2017 and 2018, there were record numbers of accelerated drug approvals based on early signs that the drug was effective, rather than the full approval process.

  • Most of these accelerated approvals were based on information from small clinical trials, without concrete evidence of drugs' effectiveness, Evaluate notes.
  • And most of these approvals have not yet been converted into full approvals based on more rigorous conditions.
  • "Mr. Gottlieb was considered a friendly face by drug developers and investors, a safe pair of hands in an administration rife with unpredictability," the authors of the analysis write.

Go deeper

Coronavirus could hit developing countries hardest

Disinfecting in Dakar, Senegal. Photo: John Wessels/AFP via Getty Images

The coronavirus is spreading most widely in countries that should be among the best equipped to handle it. There's no reason to expect that to remain the case.

Where things stand: 88% of new coronavirus cases confirmed on Wednesday came within the OECD club of wealthy nations, which together account for just 17% of the world's population. While that data is based on uneven and inadequate testing, Europe and North America are clearly in the eye of the storm.

Go deeperArrow3 mins ago - World

The Humanity First push for a coronavirus vaccine

Illustration: Aïda Amer/Axios

Policy responses to the global coronavirus crisis have been every-country-for-itself and — in the case of the U.S. and China — tinged with geopolitics.

The flipside: The scientific work underway to understand the virus and develop a vaccine has been globalized on an unprecedented scale.

Go deeperArrow10 mins ago - World

Trump attacks Schumer for impeachment in letter about coronavirus crisis

President Trump briefs reports on April 2. Photo: Win McNamee/Getty Images

President Trump accused Senate Minority Leader Chuck Schumer of being "missing in action" during the coronavirus crisis, writing in a scathing letter on Thursday that Schumer's focus on the "ridiculous impeachment hoax" resulted in New York being ill-prepared for the pandemic.

Why it matters: It's a blistering response to Schumer urging Trump to assign a senior military officer to enforce the Defense Production Act to produce more medical supplies.